Abstract:IntroductionChina has the largest number of diabetic patients in the world. In the past 2 decades, the prevalence of diabetes in China has increased dramatically, and the current status of diabetes control in the diabetic population is not satisfactory. Although insulin is currently recognized in diabetes treatment guidelines as the therapeutic option for patients not adequately controlled by diet/exercise and oral agents, the proportion of patients with type 2 diabetes using insulin is still very low, and the time when insulin therapy is initiated is relatively late. In using insulin injections, concerns about the complexity of the treatment regimen, a fear of needles, and other psychological barriers can affect insulin treatment, impacting on patient compliance and potentially resulting in a poor treatment response. Another type of insulin injection device that has become available recently, the needle-free injector, is now being used in clinical practice because of its unique features and patients' injection experiences. The aims of this study are to investigate the efficacy and safety of the needle-free injector-based insulin treatment in blood glucose control in patients with type 2 diabetes, as compared with a conventional needle-based insulin treatment, and to evaluate patient satisfaction with the different insulin delivery methods.Methods and Planned OutcomesA prospective, multicenter, randomized, open-label, parallel-group clinical trial was designed and implemented in China. A total of 420 patients with type 2 diabetes from ten research centers will be enrolled in the study. The primary efficacy endpoint is the change in the glycosylated hemoglobin (HbA1c) level from baseline to after 16weeks of treatment after randomization. Secondary efficacy endpoints include measurements of blood glucose concentrations, the rate of achieving the target HbA1c level of less than 7%, patients' quality-of-life (as determined by the SF-36 questionnaire), the insulin dose administered, compliance with insulin therapy, and patients' satisfaction with their injection device.Ethics and DisseminationThe study was approved by the Independent Ethics Committee (IEC) of Peking University Peoples Hospital and was conducted in accordance with the moral, ethical, and scientific principles of the declaration of Helsinki and the provisions of good clinical practice (GCP) in China. Written informed consent will be obtained from all participants before any study-related procedures are implemented. It is hoped that the study will provide evidence for the clinical application of the needle-free injector by providing data on its efficacy and safety, as compared with a conventional insulin pen, in the Chinese type 2 diabetes population. When available, the results will be published in an international peer-reviewed journal.Trial RegistrationClinicalTrials.gov Identifier, NCT03243903. Registration date, August 9, 2017.FundingBeijing QS Medical Technology Co., Ltd.

Insulin Dry Powder Inhalation Comparing with Subcutaneous Insulin Injection in Patients with Type 2 Diabetes: a Randomized, Controlled Clinical Trial

Clinical observation and nursing care on patients with type 2 diabetes applied as continuous subcutaneous insulin infusion

Antibody Response to Insulin Dry Powder Inhalation or Subcutaneous Regular Insulin Injection in the Patients with Poor-Controlled Type 2 Diabetes Mellitus

Multicenter Clinical Study on the Efficacy and Safety of Inhalable Insulin Aerosol in the Treatment of Type 2 Diabetes.

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

Insulin Delivery with a Needle-Free Insulin Injector Versus a Conventional Insulin Pen in Chinese Patients with Type 2 Diabetes Mellitus: A 16-Week, Multicenter, Randomized Clinical Trial (the FREE Study)

1072-P: Comparison of the Efficacy between a Needle-Free Insulin Injector and Conventional Insulin Pen in Glycemic Control in Insulin-treated Type 2 Diabetic Patients in China

[The Efficacy and Safety of Recombinant Human Insulin Injection in the Treatment of Diabetic Patients:A Multicenter, Randomized, Controlled and Open-Labeled Clinical Trial].

The Safety and Efficacy of Initiating Insulin Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Previous Oral Antidiabetic Drugs

A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing the Safety Profile of a Needle-Free Insulin Injector with Conventional Insulin Pen Injections in Chinese Patients with Type 2 Diabetes Mellitus

Comparison of Continual Insulin or Secretagogue Treatment in Type 2 Diabetic Patients with Alternate Insulin–secretagogue Administration

A 2-Way Cross-Over, Open-Labeled Trial to Compare Efficacy and Safety of Insulin Aspart and Novolin R Delivered with CSII in 21 Chinese Diabetic Patients

Efficacy and Safety of Isophane Protamine Insulin Injection 30R to Isophane Protamine Biosynthetic Human Insulin Injection 30R in Type 2 Diabetics Poorly Controlled with Oral Hypoglycemic Agents

A Prospective, Multicenter, Randomized, Open-Label, Parallel-Group Clinical Trial Comparing Patient Satisfaction And Compliance With A Needle-Free Insulin Injector Vs. Conventional Insulin Pen Injections In Chinese Patients With Type 2 Diabetes Mellitus

Efficacy Observation of the Intensivetherapy of Short-acting Insulin for 32 Patients with Type 2 Diabetes

Effectiveness and Safety of Oral Hypoglycemic Agents as Initial Treatment in Comparison to Insulin Injection in Newly Diagnosed Type 2 Diabetes Mellitus

Comparison of the efficacy between short term intensive therapy by insulin pump and multiple subcutaneous insulin injections

The Efficacy and Safety of Insulin Degludec Versus Insulin Glargine in Insulin-Naive Subjects with Type 2 Diabetes: Results of a Chinese Cohort from a Multinational Randomized Controlled Trial

Effect of Intensive Insulin Therapy on Β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: a Multicentre Randomised Parallel-Group Trial

Study on the Hypoglycemic Efficacy and Safety of Needle-Free Injection Technique in Patients with Diabetes Mellitus